EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, MeiraGTx Holdings's Enterprise Value is €1,054.96 Mil.
MeiraGTx Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €2.60 Mil. Therefore, MeiraGTx Holdings's EV-to-FCF for today is 406.54.
The historical rank and industry rank for MeiraGTx Holdings's EV-to-FCF or its related term are showing as below:
FRA:328'
s EV-to-FCF Range Over the Past 10 Years
Min: -14.25 Med: -3.54 Max: 343.75
Current: 343.75
During the past 10 years, the highest EV-to-FCF of MeiraGTx Holdings was 343.75. The lowest was -14.25. And the median was -3.54.
FRA:328's EV-to-FCF is ranked worse than 96.4% of 333
companies
in the Biotechnology industry
Industry Median: 15.57
vs FRA:328: 343.75
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
MeiraGTx Holdings's PE Ratio (TTM) for today is calculated as:
MeiraGTx Holdings's share price for today is €11.70.
MeiraGTx Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.275.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
MeiraGTx Holdings EV-to-FCF Related Terms
MeiraGTx Holdings EV-to-FCF Historical Data
* Premium members only.
The historical data trend for MeiraGTx Holdings's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, MeiraGTx Holdings's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MeiraGTx Holdings EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MeiraGTx Holdings's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where MeiraGTx Holdings's EV-to-FCF falls into.
MeiraGTx Holdings's current Enterprise Value is €1,054.96 Mil.
MeiraGTx Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.60 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MeiraGTx Holdings (FRA:328) has a EV-to-FCF of 406.54 as of Jul. 02, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on MeiraGTx Holdings and its competitors. According to the industry distribution chart, MeiraGTx Holdings ranks #321 out of 333 companies in the Biotechnology industry, placing it in the top 96.4%.
Is MeiraGTx Holdings' EV-to-FCF too high?
MeiraGTx Holdings' current EV-to-FCF is 406.54. The Biotechnology industry median EV-to-FCF is 15.57. MeiraGTx Holdings' value of 406.54 is 2511% above this industry median. Based on the distribution chart, MeiraGTx Holdings ranks #321 out of 333 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, MeiraGTx Holdings has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MeiraGTx Holdings' EV-to-FCF compare to XNCR and WVE?
According to the Biotechnology industry distribution chart, MeiraGTx Holdings ranks #321 out of 333 companies for EV-to-FCF. This places MeiraGTx Holdings in the lower half of its industry. The industry median EV-to-FCF is 15.57. MeiraGTx Holdings' value of 406.54 is 2511% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.57, based on 333 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MeiraGTx Holdings's current EV-to-FCF of 406.54 is 2511% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on MeiraGTx Holdings and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MeiraGTx Holdings's current EV-to-FCF is 406.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MeiraGTx Holdings stock overvalued right now?
Based on GuruFocus' analysis, MeiraGTx Holdings (FRA:328) is currently considered Possible Value Trap. The stock's GF Value™ is €21.80, compared to a current price of €11.70 — trading 46.3% below its estimated fair value. The current EV-to-FCF is 406.54 and 2511% above the Biotechnology industry median of 15.57. MeiraGTx Holdings' overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For MeiraGTx Holdings (FRA:328), the current EV-to-FCF is 406.54 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MeiraGTx Holdings (FRA:328) Overvalued in 2026?
Based on GuruFocus' analysis, MeiraGTx Holdings stock appears to be undervalued.
The current stock price of €11.70 is trading 46.3% below its estimated GF Value™ of €21.80.
GuruFocus considers MeiraGTx Holdings to be Possible Value Trap.
Key valuation signals for FRA:328:
EV-to-FCF: 406.54
GF Value™: €21.80 vs. price of €11.70 (46.3% below fair value)
Industry Position: 2511% above the Biotechnology median (#321 of 333)
No single metric tells the full story. See the FRA:328 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.
55GF Score
Get the complete analysis for FRA:328
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:328 has been successfully added to your 
